- Home
- CYCN vs ENSC Comparison
CYCN vs ENSC Comparison
Compare CYCN & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | ENSC |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CYCN | ENSC |
|---|---|---|
| Price | $1.54 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 132.6K |
| Earning Date | 03-03-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,855,000.00 | ★ $4,487,973.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1371.65 | 1.51 |
| 52 Week Low | $1.16 | $0.86 |
| 52 Week High | $6.25 | $8.97 |
Technical Indicators
Market Signals| Indicator | CYCN | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 48.32 | 31.45 |
| Support Level | $1.58 | $0.89 |
| Resistance Level | $2.00 | $1.10 |
| Average True Range (ATR) | 0.18 | 0.09 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 32.23 | 21.40 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.